Genetic variations in humans associated with differences in the course of hepatitis C

Biochemical and Biophysical Research Communications

Volumn 317, Issue 2, 2004, Pages 335-341

  Saito, Takafumi ^a   Ji, Guijin ^b   Shinzawa, Haruhide ^a   Okumoto, Kazuo ^a   Hattori, Etsuko ^a   Adachi, Tohru ^a   Takeda, Tadashi ^a   Sugahara, Kazuhiko ^a   Ito, Jun Itsu ^a   Watanabe, Hisayoshi ^a   Saito, Koji ^a   Togashi, Hitoshi ^a   Ishii, Keisuke ^b   Matsuura, Tadashi ^b   Inageda, Kiyoshi ^b   Muramatsu, Masaaki ^b,c   Kawata, Sumio ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HuBit Genomix Research Institute   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Genetic factor; HCV RNA; Hepatitis C virus; Immune response; Infection; Single nucleotide polymorphism; SNP

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON RECEPTOR; B7 ANTIGEN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 8; CANCER GROWTH FACTOR; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON ALPHA RECEPTOR 1; INTERFERON ALPHA RECEPTOR 2; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR L1; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 4; INTERLEUKIN 8 RECEPTOR; INTERLEUKIN 8 RECEPTOR BETA; NF KAPPA B1; PROLACTIN; STAT5A PROTEIN; TUMOR GROWTH FACTOR B1; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS CARRIER;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEPATITIS C; HUMANS; JAPAN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS); VIREMIA;

HEPATITIS C VIRUS;

EID: 11144355298     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.056     Document Type: Article

References (31)

1. Cohen J. The scientific challenge of hepatitis C. Science. 285:1999;26-30.
2. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., Furuta S., Akahane Y., Nishioka K., Purcell R.H., Alter H.J. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
3. Di Bisceglie A.M. Natural history of hepatitis C: its impact on clinical management. Hepatology. 31:2000;1014-1018.
4. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., Kiyosawa K., Aizaki H., Matsuura Y., Houghton M., Abrignani S., Miyamura T. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology. 28:1998;1117-1120.
5. Barrera J.M., Bruguera M., Ercilla M.G., Gil C., Celis R., Gil M.P., del Valle Onorato M., Rodes J., Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 21:1995;639-644.
6. Ishibashi M., Shinzawa H., Kuboki M., Tsuchida H., Takahashi T. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age- and area-related features. J. Epidemiol. 6:1996;1-7.
7. Noguchi S., Sata M., Suzuki H., Mizokami M., Tanakawa K. Routes of transmission of hepatitis C virus in an endemic rural area of Japan. Scand. J. Infect. Dis. 29:1997;23-28.
8. Kiyosawa K., Tanaka E., Sodeyama T., Yoshizawa K., Yabu K., Furuta K., Imai H., Nakano Y., Usuda S., Uemura K., Furuta S., Watanabe Y., Watanabe J., Fukuda Y., Takayama T. The south Kiso hepatitis study group, transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology. 106:1994;1596-1602.
9. Setoguchi Y., Yamamoto K., Ozaki I., Fujio N., Kariya T., Sakai T., Fujii S. Prevalence of chronic liver diseases and anti-HCV antibodies in different districts of Saga, Japan. Gastroenterol. Jpn. 26:1991;157-161.
10. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C, NIH Consensus Development Conference, Management of hepatitis C: 2002. Hepatology. 36:2002;S65-S73.
11. Ranade K., Chang M.S., Ting C.T., Pei D., Hsiao C.F., Olivier M., Pesich R., Hebert J., Chen Y.I., Dzau V.J., Curb D., Olshen R., Risch N., Cox D.R., Botstein D. High-throughput genotyping with single nucleotide polymorphisms. Genome Res. 11:2001;1262-1268.
12. Tabor H.K., Risch N.J., Myers R.M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat. Rev. Genet. 3:2002;391-397.
13. Her C., Wood T.C., Eichler E.E., Mohrenweiser H.W., Ramagli L.S., Siciliano M.J., Weinshiboum R.M. Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. Genomics. 53:1998;284-295.
14. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:1997;866-871.
15. Hilgard P., Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology. 32:2000;1069-1077.
16. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., van Kuppevelt T.H., Depla E., von Weizsacker F., Blum H.E., Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:2003;41003-41012.
17. Kirchhausen T., Nathanson K.L., Matsui W., Vaisberg A., Chow E.P., Burne C., Keen J.H., Davis A.E. Structural and functional division into two domains of the large (100- to 115-kDa) chains of the clathrin-associated protein complex AP-2. Proc. Natl. Acad. Sci. USA. 86:1989;2612-2616.
18. Peyrard M., Pan H.Q., Kedra D., Fransson I., Swahn S., Hartman K., Clifton S.W., Roe B.A., Dumanski J.P. Structure of the promoter and genomic organization of the human beta-adaptin gene (BAM22) from chromosome 22q12. Genomics. 36:1996;112-117.
19. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science. 282:1998;938-941.
20. Takikawa S., Ishii K., Aizaki H., Suzuki T., Asakura H., Matsuura Y., Miyamura T. Cell fusion activity of hepatitis C virus envelope proteins. J. Virol. 74:2000;5066-5074.
21. Ito N., Kawata S., Tamura S., Nakajima H., Kiso S., Saeki A., Oue T., Hanahusa T., Matsuzawa Y. Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects. Hepatology. 31:2000;544-545.
22. Ma W., Xia C., Ling P., Qiu M., Luo Y., Tan T.H., Liu M. Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes. Oncogene. 20:2001;1703-1714.
23. Richard E., Arredondo-Vega F.X., Santisteban I., Kelly S.J., Patel D.D., Hershfield M.S. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J. Exp. Med. 192:2000;1223-1236.
24. Pavlovic J., Zurcher T., Haller O., Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64:1990;3370-3375.
25. Hijikata M., Ohta Y., Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology. 43:2000;124-127.
26. Hijikata M., Mishiro S., Miyamoto C., Furuichi Y., Hashimoto M., Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology. 44:2001;379-382.
27. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:1991;561-569.
28. Ozkaynak E., Schnegelsberg P.N., Jin D.F., Clifford G.M., Warren F.D., Drier E.A., Oppermann H. Osteogenic protein-2. A new member of the transforming growth factor-beta superfamily expressed early in embryogenesis. J. Biol. Chem. 267:1992;25220-25227.
29. Horwitz D.A., Gray J.D., Ohtsuka K. Role of NK cells and TGF-beta in the regulation of T-cell-dependent antibody production in health and autoimmune disease. Microbes Infect. 1:1999;1305-1311.
30. Hou J., Schindler U., Henzel W.J., Wong S.C., McKnight S.L. Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity. 2:1995;321-329.
31. Lin J.X., Mietz J., Modi W.S., John S., Leonard W.J. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J. Biol. Chem. 271:1996;10738-10744.